Alnylam May Not Reach Partnership Goal for ‘09, Partner Cubist to Focus on Follow-On RSV Rx | GenomeWeb

This story has been updated to include comments from Alnylam officials and details about the company’s respiratory syncytial virus program.

By Doug Macron

Alnylam Pharmaceuticals said last week that it may not reach its previously stated goal of forging two or more new “major” industry partnerships before the end of the year despite continued interest from potential biotech and pharmaceutical allies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.